Massive Growth: Enable Injections expanding Cincinnati-area manufacturing operations and doubling headcount
Photo: Enable Injections
Enable Injections, the leading medical technology company behind the enFuse wearable technology, is expanding manufacturing operations with a new facility in the Cincinnati suburb of Springdale. The company also is investing in its corporate headquarters in the nearby suburb of Evendale.
Enable’s new 90,000-square-foot manufacturing facility will support ongoing clinical and commercial supply of enFuse, the first hands-free, wearable technology that allows patients to self-administer medications subcutaneously without an IV or syringe pump. The manufacturing facility is expected to be completed by year-end.
The investment follows the FDA approval of the company’s first enFuse combination product. EnFuse has raised more than $311 million in venture funding, according to the Cincinnati Business Courier.
What it means for Ohio
Enable plants to retain and add more than 450 jobs over the next ten years, more than doubling its current headcount, with support from the state, JobsOhio, REDI Cincinnati, and the cities of Evendale and Springdale.
The company’s expansion comes amid a wave of positive developments in Ohio’s healthcare and biotech space.
A few recent headlines:
Case Western Reserve spinoff AlensiaXR raised $3 million to accelerate development of its 3D holograms for medical students
Ohio State Spinoff Basking Biosciences raises $55 million to test stroke treatment
Cleveland’s SPR Therapeutics raises $85M for non-opioid pain treatment option
Cleveland Diagnostics secures $75 million funding to advance early-stage cancer detection
Clarametyx Biosciences, a Columbus-based BioTech, raised a $33 million Series A
Cleveland Clinic and Canon joined forces to create an imaging research center
Augment Therapy, Cleveland-based HealthTech startup, raised a $2.7 million seed plus round
University Hospitals launched the Haslam Sports Innovation Center in Cleveland with a $20 million donation
Forge Biologics, a Columbus startup, announced $620 million acquisition
What they’re saying
“Scalable, in-house manufacturing is a key pillar of Enable’s strategy to accelerate supply of our innovative enFuse technology as the Company continues to grow our roster and scope of clinical and commercial engagements with pharmaceutical partners. This new facility allows Enable to significantly expand and enhance production processes and ultimately reduce the time it takes to bring our enFuse system to patients and the medical community. We are proud to have grown our business in Ohio over the last decade and are thankful for the continued support from the state and local organizations as we expand our business operations and footprint.”
- Mike Hooven, Chairman and CEO of Enable Injections
“We and our partners at REDI Cincinnati welcome Enable Injections’ decision to grow operations in the U.S. and bring new career opportunities and investment to Ohio. Enable is a global leader in drug delivery, improving the lives of patients worldwide, and we look forward to a continued partnership.”
- JobsOhio President and CEO J.P. Nauseef
“Their decision to invest here is a testament to our collaborative efforts and Springdale’s competitive business climate and location. Production of (Enable’s) wearable drug delivery systems will not only create high-tech, high-value jobs in our city but also positively impact patient experiences worldwide. We eagerly anticipate a continued partnership with Enable Injections as they grow within our community and provide enhanced opportunities for our residents.”
- Springdale Mayor Lawrence Hawkins III
“The village of Evendale is extremely proud to provide financial support for renovations to the headquarters of Enable Injections. This company has already been a major provider of employment in the village. This agreement to remain in Evendale for 10 years provides stability to the community and for the company.”
